Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KAT2B | Q92831 | 1/20 | 0.44 |
| ▸ | BAZ2B | Q9UIF8 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.41 |
| ▸ | SYK | P43405 | 1/20 | 0.41 |
| ▸ | PSEN1 | P49768 | 1/20 | 0.37 |
| ▸ | PSEN2 | P49810 | 1/20 | 0.37 |
| ▸ | APH1B | Q8WW43 | 1/20 | 0.37 |
| ▸ | NCSTN | Q92542 | 1/20 | 0.37 |
| ▸ | APH1A | Q96BI3 | 1/20 | 0.37 |
| ▸ | PSENEN | Q9NZ42 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.35 |
| ▸ | TYK2 | P29597 | 1/20 | 0.35 |
| ▸ | VEGFA | P15692 | 1/20 | 0.34 |
| ▸ | AR | P10275 | 1/20 | 0.34 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 4/20 | 0.34 |
| ▸ | PDE4A | P27815 | 3/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25385511 | 0.88 | SLC6A2 (0.47) | SLC6A2SLC6A3SLC6A4HTR1AAR | |
| SCHEMBL7097826 | 0.85 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4HTR1AAR | |
| SCHEMBL7102061 | 0.85 | SLC6A2 (0.45) | SLC6A2SLC6A3SLC6A4HTR1AAR | |
| SCHEMBL14857951 | 0.83 | MCHR1 (0.44) | SLC6A2SLC6A3SLC6A4HTR1AAR | |
| SCHEMBL1929230 | 0.83 | KAT2B (0.53) | KAT2BBAZ2BSYKPSEN1PSEN2 | |
| SCHEMBL31383838 | 0.81 | KAT2B (0.44) | KAT2BBAZ2BSYKPSEN1PSEN2 | |
| SCHEMBL31583186 | 0.79 | KAT2B (0.43) | KAT2BBAZ2BSYKVEGFAAR | |
| SCHEMBL4504051 | 0.78 | KDM4E (0.44) | SLC6A2SLC6A3SLC6A4EGFRKDM4E | |
| SCHEMBL22040926 | 0.77 | KAT2B (0.45) | KAT2BBAZ2BSLC6A2SLC6A3SLC6A4 | |
| SCHEMBL2226051 | 0.77 | DHFR (0.48) | PIM1PIM3PIM2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2023-12-05 | — | — | US | disclosed |
| WO-2020112937-A1 | TYK2 INHIBITORS AND USES THEREOF | NIMBUS LAKSHMI, INC. (US) | 2020-06-04 | — | — | WO | disclosed |
| US-8962623-B2 | Aminopyrazine compounds | LOCUS PHARMACEUTICALS, INC. (US) | 2015-02-24 | — | — | US | disclosed |
| US-20140187529-A1 | AMINOPYRAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2014-07-03 | — | — | US | disclosed |
| WO-2012121939-A2 | AMINOPYRAZINE COMPOUNDS | LOCUS PHARMACEUTICALS, INC. (US) | 2012-09-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11834449-B2 | TYK2 inhibitors and uses thereof | TYK2, JAK2, JAK1 | KAT2B 2072/4885BAZ2B 404/4885SLC6A2 4386/4885 |
| US-20140187529-A1 | AMINOPYRAZINE COMPOUNDS | ITK, IL4I1, IL5 | KAT2B 3041/4885BAZ2B 633/4885SLC6A2 1160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.